Skip to contentB
Bone Biologics Corp
B
BBLGBone Biologics Corp Q3 2022 · 10-Q
Revenue—
Net Income-$1.22M-$1.22MN/M vs Q3 2021 EPS Diluted-$3.53-$3.53N/M vs Q3 2021 Operating Income-$1,219,277N/M Operating Cash Flowderived-$395,279N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Bone Biologics Corp · CIK 1419554 · Engraved from SEC EDGAR
ended Sep 30, 2022 · filed Nov 14, 2022 · 45 d after period end